Topic:	diabetes (dm)
Title:	New Agents for the Treatment of Diabetes.
Author:	Chirico, M.; et al
Source:	Review of Endocrinology. 1(2): 42-46. June 2007.
Abstract:	This article reviews new delivery methods for insulin and new agents for the treatment of diabetes, notably those based on the incretin phenomenon. The authors describe inhaled human insulin; pramlintide, which is an injectable synthetic analog of amylin; the incretin effect, which explains up to 60 percent of the postprandial insulin secretion of the pancreas; GLP-1 agonists, including exenatide and liraglutide; DPP-4 inhibitors, notably sitagliptin and vildagliptin; and the benefits of using these newer drugs in combination with older antidiabetic agents, particularly in patients with type 2 diabetes. The authors conclude that the GLP-1 receptor agonists and DPP-4 enzyme inhibitors offer comparable HbA1c lowering with few side effects and may also lead to weight loss. 1 figure. 3 tables. 24 references.
Format:	Journal Article
Language:	English.
Major Keywords:	Diabetes Mellitus. Type 2 Diabetes. Drug Therapy. Incretin Mimetics. Insulin. Administration and Dosage. Blood Glucose.
Minor Keywords:	Pramlintide. Exenatide. Sitagliptin. Inhaled Insulin. Incretins. Physiology. Glycosylated Hemoglobin. Drug Effects. Patient Selection. Patient Care Management.
Publication Number:	DMJA13030.
Return to Search Results